BackgroundCheck.run
Search For

George M Coppola, 5216 Ennis Dr, Hazlet, NJ 07730

George Coppola Phones & Addresses

16 Ennis Dr, Hazlet, NJ 07730    917-6238217   

4 Fernwood Pl, Old Bridge, NJ 08857   

1981 61St St, Brooklyn, NY 11204   

1981 61St St #1, Brooklyn, NY 11204   

Saylorsburg, PA   

Citrus Heights, CA   

New York, NY   

Monmouth, NJ   

Irvine, CA   

Work

Company: Vonage Nov 2007 Position: Senior marketing manager

Education

School / High School: Pace University- New York, NY Aug 1994 Specialities: Bachelor of Business Administration in Marketing

Skills

Lean Six Sigma Yellow Belt • proficient in Microsoft Excel • PowerPoint • Word • TNS • eTelmar • MRI • Awareness Modeling • Compose and Mac applications

Mentions for George M Coppola

George Coppola resumes & CV records

Resumes

George Coppola Photo 28

Integrated Media Director

Location:
16 Ennis Dr, Hazlet, NJ 07730
Industry:
Marketing And Advertising
Work:
Omd Usa Apr 2018 - Sep 2018
Group Director
Fit Apr 2018 - Sep 2018
Professor
Gmlv Apr 2018 - Sep 2018
Integrated Media Director
Media Assembly Feb 2016 - Jun 2017
Vice President Integrated Communications Director
Mediavest Jul 2014 - Feb 2016
Vice President Connections Director
Vonage Nov 2007 - Jul 2014
Senior Marketing Manager
Maxus Sep 2004 - Nov 2007
Senior Partner Communications Director
Aka Sep 2002 - Nov 2004
Associate Media Director
Grey Direct Aug 1997 - Sep 2000
Media Supervisor
Bates Usa Sep 1996 - Aug 1997
Media Planner
Griffin Bacal May 1994 - Sep 1996
Media Planner
Education:
Pace University 1990 - 1994
Bachelors, Bachelor of Business Administration, Marketing
Bishop Ford Central Catholic High School 1990
Skills:
Media Planning, Digital Marketing, Integrated Marketing, Direct Marketing, Mobile Marketing, Digital Strategy, Advertising, Marketing, Marketing Communications, Online Advertising, Marketing Strategy, Digital Media, Brand Management, Media Buying, Sem, Interactive Marketing, Social Media Marketing, Email Marketing, New Media, Web Analytics, Online Marketing, Strategy, Analytics, Media Strategy, Mobile Advertising, Direct Response, Strategic Partnerships, B2B Marketing, Lead Generation, Google Adwords, Brand Development, Interactive Advertising, Ppc, Customer Acquisition, Multi Channel Marketing, Relationship Marketing, Marketing Management, Management, Social Media, Search Engine Marketing, Sponsorship, E Commerce, Media Tools, Business Development, Leadership, Advertising Sales, Business Strategy, Strategic Planning, Salesforce.com, Customer Insight
Languages:
Italian
Certifications:
Lean Six Sigma Yellow Belt
George Coppola Photo 29

George Coppola

George Coppola Photo 30

George Coppola

George Coppola Photo 31

George Coppola - Hazlet, NJ

Work:
Vonage Nov 2007 to 2000
Senior Marketing Manager
MAXUS/Media Marketing Solutions Sep 2004 to Nov 2007
Senior Partner- Communications Director
AKA, Inc Oct 2002 to Sep 2004
Associate Media Director - Footlocker, Lady's Footlocker, Kid's Footlocker and Champs Sports
Cablevision Systems Corporation Jul 2002 to Sep 2002
Media Manager - The Wiz
Grey Direct Jul 1997 to Apr 2001
Media Supervisor - Renaissance Cruises
Bates USA Jul 1996 to Jul 1997
Media Planner - Footlocker, Lady's Footlocker, Kid's Footlocker and Champs Sports
Griffin Bacal, Inc Sep 1994 to Jul 1996
Media Planner - Milton Bradley
Education:
Pace University - New York, NY Aug 1994
Bachelor of Business Administration in Marketing
Skills:
Lean Six Sigma Yellow Belt, proficient in Microsoft Excel, PowerPoint, Word, TNS, eTelmar, MRI, Awareness Modeling, Compose and Mac applications

Publications & IP owners

Us Patents

Recombinant -Galactosidase A Therapy For Fabry Disease

US Patent:
6461609, Oct 8, 2002
Filed:
Jan 29, 1997
Appl. No.:
08/790491
Inventors:
David Hudgins Calhoun - Leonia NJ
George Coppola - Hartsdale NY
Assignee:
Research Foundation of the City University of New York - New York NY
International Classification:
A61K 3847
US Classification:
424 9461, 435208, 4353201
Abstract:
Fabry disease results from an X-linked deficiency in the enzyme -galactosidase A. The present invention is directed to recombinant human -galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of -galactosidase A are also provided.

Recombinant Α-Galactosidase A Therapy For Fabry Disease

US Patent:
7011831, Mar 14, 2006
Filed:
Sep 4, 2002
Appl. No.:
10/234524
Inventors:
David Hudgins Calhoun - Leonia NJ, US
George Coppola - Hartsdale NY, US
Assignee:
Research Corporation Technologies, Inc. - Tucson AZ
International Classification:
A61K 38/47
C12N 9/40
C12N 15/00
US Classification:
424 9461, 435208, 4353201
Abstract:
Fabry disease results from an X-linked deficiency in the enzyme α-galactosidase A. The present invention is directed to recombinant human α-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of α-galactosidase A are also provided.

Recombinant .Alpha.-Galactosidase A Therapy For Fabry Disease

US Patent:
5179023, Jan 12, 1993
Filed:
May 7, 1990
Appl. No.:
7/520312
Inventors:
David H. Calhoun - Leonia NJ
George Coppola - Hartsdale NY
Assignee:
Research Corporation Technologies, Inc. - Tucson AZ
International Classification:
C12N 1500
C12N 940
C12N 1506
C12N 1586
US Classification:
4353201
Abstract:
Fabry disease results from an X-linked deficiency in the enzyme. alpha. -galactosidase A. The present invention is directed to recombinant human. alpha. -galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of. alpha. -galactosidase A are also provided.

Recombinant .Alpha.-Galactosidase A Therapy For Fabry Disease

US Patent:
5658567, Aug 19, 1997
Filed:
Nov 22, 1993
Appl. No.:
8/155734
Inventors:
David Hudgins Calhoun - Leonia NJ
George Coppola - Hartsdale NY
Assignee:
Research Corporation Technologies, Inc. - Tucson AZ
International Classification:
A61K 3846
A61K 3847
C12N 940
C12N 1554
US Classification:
424 9461
Abstract:
Fabry disease results from an X-linked deficiency in the enzyme. alpha. -galactosidase A. The present invention is directed to recombinant human. alpha. -galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of. alpha. -galactosidase A are also provided.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.